Abstract
This Viewpoint discusses how patient assistance programs help patients pay for expensive name-brand drugs, which help ensure profit, and recommends anti-kickback statutes be used to ensure the programs help those most in need.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JAMA: The Journal of the American Medical Association
Paper Title
Journal
Date
